TABLE 1.
Clinical characteristics of study populations.
| Discovery group | Validation group | |||||
|---|---|---|---|---|---|---|
| Responders (n = 89) | Non-responders (n = 43) | p-value | Responders (n = 48) | Non-responders (n = 39) | p-value | |
| Age, years, mean (CI) a | 69.6 (67.8–71.4) | 68.5 (66.6–70.4) | 0.408 | 69.0 (66.6–71.4) | 67.3 (65.0–69.5) | 0.306 |
| Gender, male, n (%) b | 60 (67.4) | 32 (74.4) | 0.412 | 33 (68.8) | 26 (66.7) | 0.836 |
| Ethnicity, Han, n (%) b | 89 (100.0) | 41 (95.3) | 0.103 | 48 (100.0) | 39 (100.0) | 1.000 |
| Study eye, right, n (%) b | 53 (59.6) | 24 (55.8) | 0.683 | 22 (45.8) | 20 (51.3) | 0.613 |
| Lesion type, AMD, n (%) b | 40 (44.9) | 22 (51.2) | 0.502 | 38 (79.2) | 26 (66.7) | 0.189 |
| Clinical characteristics | ||||||
| BCVA before treatment, ETDRS letters, (CI) a | 39.0 (34.1–43.9) | 42.2 (35.4–49.0) | 0.462 | 41.9 (35.6–48.3) | 43.8 (35.7–51.9) | 0.710 |
| BCVA after treatment, ETDRS letters, (CI) c | 46.3 (41.5–51.2) | 44.4 (37.0–51.7) | 0.638 | 48.7 (42.6–54.9) | 49.0 (41.7–56.3) | 0.980 |
| Change of BCVA, ETDRS letters, (CI) c | 7.3 (4.7–10.0) | 2.2 (-0.5–4.9) | 0.008 | 6.8 (2.8–10.9) | 5.2 (0.84–9.6) | 0.484 |
| IOP before treatment, mmHg, (CI) | 14.64 (13.95–15.34) | 15.21 (14.31–16.11) | 0.236c | 13.88 (12.90–14.86) | 14.62 (13.52–15.72) | 0.312a |
| IOP after treatment, mmHg, (CI) c | 13.93 (13.35–14.51) | 13.95 (13.18–14.73) | 0.965 | 12.95 (11.98–13.91) | 14.32 (13.28–15.36) | 0.047 |
| Change of IOP, mmHg, (CI) | -0.71 (-1.34∼-0.09) | -1.26 (-1.86∼-0.65) | 0.082c | -0.93 (-1.66∼-0.20) | -0.30 (-1.11–0.51) | 0.245a |
| CRT before treatment, μm, (CI) c | 502.8 (458.8–546.8) | 524.5 (451.2–597.8) | 0.928 | 397.5 (351.8–443.3) | 348.9 (304.0–393.7) | 0.069 |
| CRT after treatment, μm, (CI) c | 342.9 (315.0–370.8) | 530.3 (455.0–605.7) | <0.001 | 260.7 (233.3–288.2) | 364.7 (319.1–410.4) | <0.001 |
| Change of CRT, μm, (CI) c | -159.9 (-187.1∼-132.7) | 5.9 (-5.8–17.5) | <0.001 | -136.8 (-167.0∼-106.7) | 15.9 (-1.7–33.5) | <0.001 |
| Systemic diseases at baseline, n (%) b | ||||||
| Hypertension | 29 (32.6) | 18 (41.9) | 0.297 | 13 (27.1) | 13 (33.3) | 0.527 |
| Diabetes | 14 (15.7) | 3 (7.0) | 0.259 | 8 (16.7) | 3 (7.7) | 0.353 |
| Dyslipidemia | 5 (5.6) | 3 (7.0) | 1.000 | 0 (0.0) | 2 (5.1) | 0.198 |
| Cardiac/cerebrovascular diseases | 11 (12.4) | 3 (7.0) | 0.522 | 0 (0.0) | 2 (5.1) | 0.198 |
| Treatments, n (%) b | ||||||
| Antihypertensives | 24 (27.0) | 15 (34.9) | 0.350 | 8 (16.7) | 14 (35.9) | 0.040 |
| Antihyperglycemics | 12 (13.5) | 2 (4.7) | 0.214 | 6 (12.5) | 1 (2.6) | 0.194 |
| Antihyperlipidemics | 3 (3.4) | 4 (9.3) | 0.312 | 1 (2.1) | 0 (0.0) | 1.000 |
BCVA, best corrected visual acuity; ETDRS, early treatment diabetic retinopathy study; IOP, intraocular pressure; CRT, central retinal thickness.
a
: Independent-samples t test.
b
: Chi-square test.
c
: Mann-Whitney U test.